Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent Bacterial Vaginosis Clear all

Conditions: Bacterial Vaginosis
Interventions: Vaginal acidifying gel (RepHresh), Metronidazole control; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Bacterial Vaginosis
Interventions: Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more

Conditions: Bacterial Vaginosis
Interventions: Lactobacillus crispatus CTV-05, Metronidazole, Placebo; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Candidiasis, Vulvovaginal
Interventions: OCF001 Intravaginal Gel, Placebo Gel; Drug
Lead sponsor: Sano Chemicals Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacterial Vaginosis
Interventions: Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • San Diego, California • Metairie, Louisiana + 1 more

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Metronidazole (male partner), Placeob (male partner); Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 50 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pell City, Alabama

Conditions: Recurrent Bacterial Vaginosis
Interventions: Oral tinidazole; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Bacterial Vaginosis
Interventions: Secnidazole 2 GM Oral Granules; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions: Not listed
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Bacterial Vaginosis, Vaginal Flora Imbalance
Interventions: Flourish Vaginal Care System; Combination Product
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Concord, New Hampshire

Conditions: Recurrent Bacterial Vaginosis
Interventions: Vaginal microbiome transplant, Oral Metronidazole, Sterile saline; Biological · Drug · Other
Lead sponsor: Douglas Kwon; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Bacterial Vaginosis
Interventions: Flourish HEC Vaginal Care System; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Tucson, Arizona • Encino, California • Los Angeles, California + 30 more

Conditions: Bacterial Vaginosis
Interventions: Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components); Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rosemont, Pennsylvania

Conditions: Bacterial Vaginosis
Interventions: tinidazole, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more

Search by objective public record fields.

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

LACTIN-V Study for Recurrent Bacterial Vaginosis

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Clinical Trial to Survey Results of Flourish Vaginal Care System for Recurrent Bacterial Vaginosis

Vaginal Microbiota Transplant

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

Flourish HEC to Prevent Recurrence of BV

Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)